Evaxion reports Q3 2026 loss and pivots to oncology with new cancer vaccine data
+2 new sources since this summary was written
Evaxion A/S announced its third‑quarter 2026 financial results, posting a net loss of $3.5 million. The company said it is refocusing its strategy on immuno‑oncology, advancing personalized vaccine EVX‑01 and off‑the‑shelf candidates EVX‑04 and EVX‑05, and extended its cash runway into late 2027. Clinical updates highlighted a 75% objective response rate for EVX‑01 in melanoma and the firm won the 2026 International Prix Galien Award for its AI‑Immunology platform.
Why it matters
The loss and cash position indicate the company will need to fund its oncology program through the end of 2027, making runway length a key metric for investors. The strong response data for EVX‑01 and the strategic pivot may improve the company’s partnership prospects and valuation, as noted in the company’s presentation.
Key facts
- 1Evaxion reported a Q3 2026 net loss of $3.5 million. tradingview.com
- 2Cash and cash equivalents were $13.3 million as of September 30, 2026. tradingview.com
- 3The cash runway has been extended to the end of 2027. tradingview.com
- 4The company is refocusing its strategy on immuno‑oncology, prioritising AI‑Immunology for cancer vaccine development. finanznachrichten.de
- 5Evaxion will advance off‑the‑shelf vaccines EVX‑04 and EVX‑05 toward clinical development. finanznachrichten.de
- 6EVX‑01 showed a 75% objective response rate in its melanoma trial. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.